Search Within

Deborah Mulford

Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
  3. Book Section (1)
Groups
  1. Department of Medicine (8)
  2. Hematologic Malignancies, Division of (8)
  3. Adult Leukemia (7)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  5. Center for Hematologic Malignancies (7)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (7)

More Groups

People
  1. Joseph Jurcic (8)
  2. David Scheinberg (7)
  3. Michael Mcdevitt (4)
  4. Steven Larson (4)
  5. Chaitanya Divgi (3)
  6. Mark Weiss (3)

More People

Years
  1. 2010 (1)
  2. 2008 (1)
  3. 2007 (1)
  4. 2005 (1)
  5. 2004 (3)
  6. 2003 (1)
Publications
  1. Blood (3)
  2. Cancer Biotherapy and Radiopharmaceuticals (1)
  3. Clinical Cancer Research (1)
  4. Expert Opinion on Biological Therapy (1)
  5. General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology (1)
  6. Journal of Nuclear Medicine (1)
Publishers
  1. American Society of Hematology (3)
  2. American Association for Cancer Research (1)
  3. Mary Ann Liebert, Inc (1)
  4. Society of Nuclear Medicine (1)
  5. Springer Netherlands (1)
  6. Taylor & Francis Group (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Journal Article

    Rosenblat, T. L.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Sequential cytarabine and alpha-particle immunotherapy with bismuth-213 ((213)Bi)-labeled-HuM195 (lintuzumab) for acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Weiss, M. A.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Monoclonal antibody therapy of cancer
    Book Section

    Jurcic, J. G.; Mulford, D. A.; Scheinberg, D. A.
    In Kaufman, H. L.; Wolchok, J. D. (Eds.) General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology (2007)

    Fulltext@MSK | Save
  • The promise of targeted α-particle therapy
    Journal Article

    Mulford, D. A.; Scheinberg, D. A.; Jurcic, J. G.
    Journal of Nuclear Medicine (2005)

    Fulltext@MSK | Save
  • Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
    Meeting Abstract

    Mulford, D. A.; Pandit-Taskar, N.; McDevitt, M. R.; Finn, R. D.; Weiss, M. A.; Apostolidis, C.; Morgenstern, A.; Divgi, C. R.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Bismuth-labeled anti-CD33 antibody for elimination of minimal residual disease in acute myeloid leukemia
    Meeting Abstract

    Mulford, D.; Divgi, C.; Mcdevitt, M.; Sgouros, G.; Finn, R.; Larson, S.; Apostolidis, C.; Morgenstern, A.; Scheinberg, D.; Jurcic, J.
    Cancer Biotherapy and Radiopharmaceuticals (2004)

    Fulltext@MSK | Save
  • Antibody-based treatment of acute myeloid leukaemia
    Journal Article

    Mulford, D. A.; Jurcic, J. G.
    Expert Opinion on Biological Therapy (2004)

    Fulltext@MSK | Save
  • Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy
    Meeting Abstract

    Mulford, D. A.; Maslak, P. G.; Weiss, M. A.; Scheinberg, D. A.; Jurcic, J. G.
    Blood (2003)

    Fulltext@MSK | Save